Robert B. Stein

Dr. Robert B. Stein is the Principal Consultant at RBS Biotech. He was the former Chief Scientific Officer of Agenus Inc. In this role, Dr. Stein led Agenus’ Research Preclinical Development and Translational Medicine functions. He helped shape clinical development strategy for vaccines and adjuvants. Additionally, he led integration of the 4-Antibody acquisition, which included the company’s fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his 30 years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta® and Eliquis®. Prior to joining Agenus he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University.